MX2012002199A - Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina. - Google Patents

Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.

Info

Publication number
MX2012002199A
MX2012002199A MX2012002199A MX2012002199A MX2012002199A MX 2012002199 A MX2012002199 A MX 2012002199A MX 2012002199 A MX2012002199 A MX 2012002199A MX 2012002199 A MX2012002199 A MX 2012002199A MX 2012002199 A MX2012002199 A MX 2012002199A
Authority
MX
Mexico
Prior art keywords
phenylsulfanyl
dimethyl
phenyl
new compositions
pip erazine
Prior art date
Application number
MX2012002199A
Other languages
English (en)
Spanish (es)
Inventor
Astrid Maria Hoejer
Pernille Gundorf
Jens Kateb
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43628463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2012002199A publication Critical patent/MX2012002199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2012002199A 2009-08-24 2010-08-23 Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina. MX2012002199A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23622309P 2009-08-24 2009-08-24
DKPA200900950 2009-08-24
PCT/DK2010/050216 WO2011023194A2 (en) 2009-08-24 2010-08-23 New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Publications (1)

Publication Number Publication Date
MX2012002199A true MX2012002199A (es) 2012-03-16

Family

ID=43628463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002199A MX2012002199A (es) 2009-08-24 2010-08-23 Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.

Country Status (32)

Country Link
US (3) US20120189697A1 (enExample)
EP (1) EP2470166B1 (enExample)
JP (1) JP2013502446A (enExample)
KR (1) KR20120065328A (enExample)
CN (1) CN102639117A (enExample)
AU (1) AU2010289022B2 (enExample)
BR (1) BR112012003280A2 (enExample)
CA (1) CA2769872A1 (enExample)
CL (1) CL2012000457A1 (enExample)
CO (1) CO6612204A2 (enExample)
CR (1) CR20120058A (enExample)
DK (1) DK2470166T3 (enExample)
DO (1) DOP2012000050A (enExample)
EA (1) EA021321B1 (enExample)
ES (1) ES2427628T3 (enExample)
GE (1) GEP20135950B (enExample)
HR (1) HRP20130819T1 (enExample)
IL (1) IL217914A0 (enExample)
MA (1) MA33598B1 (enExample)
ME (1) ME01602B (enExample)
MX (1) MX2012002199A (enExample)
NZ (1) NZ598083A (enExample)
PL (1) PL2470166T3 (enExample)
PT (1) PT2470166E (enExample)
RS (1) RS52959B (enExample)
SG (1) SG178325A1 (enExample)
SI (1) SI2470166T1 (enExample)
SM (1) SMT201300108B (enExample)
TN (1) TN2012000038A1 (enExample)
UA (1) UA105057C2 (enExample)
WO (1) WO2011023194A2 (enExample)
ZA (1) ZA201201360B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
KR101820181B1 (ko) * 2010-04-30 2018-02-28 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
BR112012027782A2 (pt) 2010-04-30 2016-08-02 Takeda Pharmaceutical tablete entérico
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3184104B1 (en) 2015-12-23 2018-09-12 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
WO2018065348A1 (en) 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN112006995A (zh) * 2020-08-14 2020-12-01 石药集团中奇制药技术（石家庄）有限公司 一种氢溴酸伏硫西汀片的制备方法
CN112245432B (zh) * 2020-11-05 2021-12-21 东南大学 一种1-二苯甲基-4-甲基哌嗪类化合物在制备抗抑郁症药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6866146B2 (en) 2001-10-09 2005-03-15 Christian M. Heesch Protective case for string instruments
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
KR101533268B1 (ko) * 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
US8722684B2 (en) * 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
PT2470166E (pt) 2013-10-02
SG178325A1 (en) 2012-03-29
EP2470166B1 (en) 2013-08-14
UA105057C2 (uk) 2014-04-10
WO2011023194A2 (en) 2011-03-03
SMT201300108B (it) 2013-11-08
TN2012000038A1 (en) 2013-09-19
ZA201201360B (en) 2013-05-29
CL2012000457A1 (es) 2013-01-25
DK2470166T3 (da) 2013-09-08
EP2470166A2 (en) 2012-07-04
ME01602B (me) 2014-09-20
US20150150867A1 (en) 2015-06-04
PL2470166T3 (pl) 2013-11-29
IL217914A0 (en) 2012-03-29
GEP20135950B (en) 2013-10-25
CO6612204A2 (es) 2013-02-01
ES2427628T3 (es) 2013-10-31
EA201290116A1 (ru) 2012-06-29
MA33598B1 (fr) 2012-09-01
SI2470166T1 (sl) 2014-03-31
CN102639117A (zh) 2012-08-15
AU2010289022B2 (en) 2013-03-14
RS52959B (sr) 2014-02-28
US20120189697A1 (en) 2012-07-26
CR20120058A (es) 2012-04-26
JP2013502446A (ja) 2013-01-24
WO2011023194A3 (en) 2011-12-01
BR112012003280A2 (pt) 2017-05-23
US20160256398A1 (en) 2016-09-08
KR20120065328A (ko) 2012-06-20
HRP20130819T1 (en) 2013-09-30
CA2769872A1 (en) 2011-03-03
AU2010289022A1 (en) 2012-03-08
EA021321B1 (ru) 2015-05-29
DOP2012000050A (es) 2012-07-31
NZ598083A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
MX2012002199A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]pip erazina.
MY155288A (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
IL214942A (en) N, n– Dimethyl-5– (2-methyl-6 - ((5-methylpyrazine-2-yl) carbamole) Benzoporen-4-Iloxy) Pyrimidine-2-carboxamide and the salts common in its pharmacies, pharmaceuticals containing them and their uses in the preparation of drugs
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
MX2010004688A (es) Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.
IN2012DN03337A (enExample)
IL200561A (en) Heterocyclic inhibitors of aspartate protease or their tautomers, their acceptable pharmacy salt, their pharmacy composition and their use
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
MY156630A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
JO2781B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
NZ708959A (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
MY169295A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2009062036A3 (en) Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
MX2010005048A (es) Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
SG165254A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MX2012002479A (es) Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.
EA201301136A2 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CY1114956T1 (el) Νεες συνθεσεις 1-[2-(2,4-διμεθυλο-φαινυλοσουλφανυλο)-φαινυλο]πιπεραζινης
WO2008110586A3 (en) New process for the preparation of levocetirizine and intermediates thereof
TH134103A (th) องค์ประกอบใหม่ของ 1-[2-(2,4-ไดเมทธิล-ฟีนิลซัลฟานิล)-ฟีนิล]พิเพอราซีน (1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted